Novo Nordisk A/S: Oral semaglutide demonstrates a 14% - GlobeNewswire

Novo Nordisk A/S: Oral semaglutide demonstrates a 14% GlobeNewswireNovo Nordisk's new pill shows 14% reduction in heart attacks in diabetics MintSemaglutide: What impact does it really have on heart health? Medical News TodayNovo Nordisk’s oral diabetes drug reduces heart-related risks by 14 percent The Financial ExpressThe pill version of Ozempic can reduce the risk of heart attacks and strokes, study says Quartzy